News

ICON6 ovarian cancer results may resurrect cediranib

Publish date: October 4, 2013

 

AT THE EUROPEAN CANCER CONGRESS 2013

Prof. Ledermann and his coauthors reported no relevant disclosures. AstraZeneca provided the study drug. Britain’s Medical Research Council sponsored the trial.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Metronidazole needed for complete pelvic inflammatory disease coverage
MDedge ObGyn
Vitrification efficiently preserves oocytes, embryos
MDedge ObGyn
High-dose intravaginal metronidazole/miconazole may help BV
MDedge ObGyn
M. genitalium demands new STI treatment strategy
MDedge ObGyn
Biweekly 5-fluorouracil cream beat back cervical neoplasia
MDedge ObGyn
New Candida species isolated in U.S.
MDedge ObGyn
Catheter UTIs cleared with old-fashioned oxychlorosene flush
MDedge ObGyn
TRINOVA-1 signals new direction in ovarian cancer
MDedge ObGyn
New option for treating menopausal vasomotor symptoms receives FDA approval
MDedge ObGyn
Ospemifene for dyspareunia in postmenopausal women is well tolerated
MDedge ObGyn